Osman Vefa Gul

Dr. Osman Vefa Gul

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

3 December 2023 in Radiation Physics and Chemistry
Verified
Journal Article
Closed access
OGOsman Vefa Gul
Osman Vefa Gul
MDMursel Duzova
Mursel Duzova

1 December 2021 in Transplant Immunology
Verified
Journal Article
Closed access
MDMursel Duzova
Mursel Duzova
HBHamit Basaran
Hamit Basaran
GIGokcen Inan
Gokcen Inan
OGOsman Vefa Gul
Osman Vefa Gul
OEOrhan Onder Eren
Orhan Onder Eren
MKMuslu Kazım Körez
Muslu Kazım Körez

7 October 2022 in Radiation Physics and Chemistry
Verified
Journal Article
Closed access
OGOsman Vefa Gul
Osman Vefa Gul
NBNihal Buyukcizmeci
Nihal Buyukcizmeci
HBHamit Basaran
Hamit Basaran

20 February 2024 in Radiation Physics and Chemistry
Verified
Journal Article
Closed access
OGOsman Vefa Gul
Osman Vefa Gul
HDHikmettin Demir
Hikmettin Demir
HBHamit Basaran
Hamit Basaran
GKGul Kanyılmaz
Gul Kanyılmaz

4 October 2021 in Journal of the Egyptian National Cancer Institute
Verified
Journal Article
Open access
PDF file
OGOsman Vefa Gul
Osman Vefa Gul
GIGokcen Inan
Gokcen Inan
HBHamit Basaran
Hamit Basaran
Background: Cancer is one of the leading causes of death worldwide. According to GLOBOCAN estimates, there were 341,831 deaths from cervical cancer in 185 countries in 2020. The aim of this study was to compare equieffective dose (EQD2) at 2 Gy per fraction by using dose volume histograms (DVHs) derived from external beam radiotherapy (EBRT) and high-dose rate brachytherapy (HDR-BRT) treatment plans used in cervical cancer radiotherapy. Methods: Fifteen patients with stage IIB-IIIB cervical cancer were included in this retrospective study. Treatment with three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) was planned for all patients in 28 fractions, with a total of 50.4 Gy to be delivered to the whole pelvic region. After EBRT, manual optimization (MO) or inverse optimization (IO) HDR-BRT plans were created in 4 fractions with a total of 28 Gy. The plans obtained were grouped as IMRT + IO, IMRT + MO, 3DCRT + IO, and 3DCRT + MO by calculating EQD2s among these plans. D90, D95, and D98 values were compared in all plans for CTVHR total EQD2. In addition, EQD2 values ​for critical organs at risk (OARs) such as rectum, bladder, small intestine, and sigmoid were compared in all plans for volumes of 2 cm3, 1 cm3, and 0.1 cm3, respectively. Results: There was no significant difference between the treatment groups in terms of CTVHR D90 and CTVIR D90 values; However, CTVHR D95 (p = 0.000) and CTVHR D98 (p = 0.000) values ​were found to be better in IMRT + IO technique. The IMRT + IO technique provided better protection for 2 cm3, 1 cm3, and 0.1 cm3 volumes of OARs compared to other techniques. Conclusions: Considering all parameters such as CTVHR, CTVIR, rectum, bladder, small intestine, and sigmoid, combination of IMRT + IO treatment option was found to be significantly superior in total EQD2 calculations compared to other plans.